Cargando…
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
The concentrations of cathepsin D (Cath D), urokinase (uPA) and two plasminogen activator inhibitors (PAI-1 and PAI-2) were analysed in the cytosols of 130 human mammary tumours (43 benign tumours and 87 primary and unilateral breast carcinomas). uPA, PAI-1 and PAI-2 levels were measured by antigeni...
Autores principales: | Foucré, D., Bouchet, C., Hacène, K., Pourreau-Schneider, N., Gentile, A., Martin, P. M., Desplaces, A., Oglobine, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977447/ https://www.ncbi.nlm.nih.gov/pubmed/1931618 |
Ejemplares similares
-
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994) -
Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.
por: Bouchet, C., et al.
Publicado: (1998) -
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
por: Herszényi, László, et al.
Publicado: (2008) -
In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.
por: Abaza, M. S., et al.
Publicado: (1998) -
In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)